Our Team. Highly experienced team in healthcare and CBD. Driven by safety and efficacy. Improving the lives of people worldwide.
Co-Founder & CEO
Entrepreneur with 20 years of healthcare experience with a passion for building companies at the intersection of science and technology - epigenomics, diagnostics, digital health, and eye tracking. Focused on commercializing new products and technologies within wellness and health. Mother of two boys, raised in Hawaii, and a Crossfitter. BS in biology from Brown University.
Caitlyn is committed to realizing the potential of pure, science and data driven CBD.
PHYLLIS WHITELEY, PhD
Serial entrepreneur with 25+ years of healthcare experience. Builds, invests and creates companies within therapeutics, diagnostics, life science tools, digital health, and personalized medicine. Sits on multiple boards and is dedicated to helping social entrepreneurs address the problems of poverty, empower women, and build resilience to climate change. Passion for transformative life science innovations, healthcare solutions, global health, mentorship, and locavore cooking. BA in Chemistry and Ph.D in Pharmacology from Washington University, St. Louis, Missouri.
Phyllis is committed to developing CBD drugs that have the potential to treat disease.
Entrepreneur and investor with 15+ years sitting at the intersection of design and business, bringing new products and companies to life for startups and F1000 companies. Expert at incubating, investing, and advising on design and Go-to-Market for early stage startups. Sits on multiple Boards in healthcare, education, and fintech. BA from James Madison University and MBA from Babson College.
Randall’s driving force is to make the world a more innovative, better place at scale, through companies like Nalu.
MATTHEW ROBERTS, PhD
Chief Technology Advisor
Chief Technology Officer (CTO) with 25+ years of experience leading science, technology, and innovation for global leaders in Food and Nutrition. His experience and expertise span food, nutrition, operations, process scale-up, clinical trials, regulatory and quality. He has worked for large consumer packaged good companies and chemical ingredient companies including - Nestle, Abbott Nutrition, Pharmavite - The Nature’s Bounty Company, Chromadex, and the Health & Happiness Group. Matthew has authored 30+ publications and patents and received his BS from Purdue University, his PhD from Cornell, and an Executive MBA from Washington University, St. Louis.
Matthew has a passion for delivering ingredients and bio-actives to consumers which promote good mental health and well-being through a healthy endocannabinoid system. Matthew is the father of 3 children, an avid hiker and runner, and a voracious consumer of science journalism and philosophy.
ALEX DORENBAUM, MD
Chief Medical Officer
A world class physician with more than 25+ years of experience in healthcare as a physician and drug development expert. He has served as the Chief Medical Officer and held leading roles at Genentech, BioMarin Pharmaceutical, Chiron, Reneo Pharmaceuticals, Allakos, and Lumena Pharmaceuticals. Developed 30+ drugs in allergy, HIV/AIDS, pulmonary, immunological, cardiovascular, metabolic, and pediatric diseases. Currently a Clinical Professor at Stanford School of Medicine where he sees patients weekly. Received his MD from The National Autonomous University in Mexico City, Residency at University of Texas Health Science Center, and Fellowship at Baylor College of Medicine.
When Alex was at UCSF he was pioneering therapies to prevent transmission of HIV infection and was recommending cannabis to pediatric patients back in the early 90’s.
SAM BANISTER, PhD
A Team Leader in Medicinal Chemistry at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Research on new cannabinoid drugs for epilepsy, neuropathic pain, depression, anxiety, substance abuse, and more. Authored two book chapters on the chemistry of synthetic cannabinoids, 70+ peer-reviewed publications, postdoc at Stanford University, BSc and PhD in Chemistry, University of Sydney.
KEN MACKIE, MD
A Distinguished Professor in Psychological and Brain Sciences at the Gill Center for Bimolecular Science, Indiana University. Research in neuroscience, regulation of CB1 receptors, regulation of endocannabinoid production, and role of novel cannabinoid receptors. 400 publications with 100+ publications on cannabinoids and the endocannabinoid system, ScB in Engineering, Brown University, MD from Yale University.
JOICE THOMAS, PhD
An experienced medicinal chemist at the Michelson Center for Convergent Bioscience, University of Southern California. Expertise in synthetic route development, structure-based drug design, and ligand-based drug design. Focused on small molecule drug discovery in cancer and antivirals that target GPCRs, especially opioid receptors for the development of safer drugs to treat opioid overdose. 50+ publications in peer-reviewed journals and 6 patents. PhD in Chemistry from KU Leuven, Belgium.